Policy & Regulation
Acadia Pharmaceuticals Names Subbiah as SVP and Global Head of Medical Affairs and Chief Medical Officer
6 November 2019 - - US-based biopharmaceutical company Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) has appointed Ponni Subbiah, M.D., M.P.H., as senior vice president, global head of medical affairs and chief medical officer, the company said.
Subbiah will report to Serge Stankovic, M.D., M.S.P.H., Acadia's president and be responsible for corporate medical affairs including medical strategy, scientific communications, and medical science liaison activities.
Subbiah is a neurologist with over 20 years of experience in the pharmaceutical industry and global health sector.
She has led the development and execution of medical and clinical research strategies in various therapeutic areas, including neurology, psychiatry, opioid addiction, pain, oncology, diabetes, urology, inflammation, respiratory, and infectious diseases.
Subbiah was most recently chief medical officer for Indivior Inc., with responsibility for pharmacovigilance and medical affairs globally.
She was also the company spokesperson at policy discussions including testifying at the presidential Commission on Combating Drug Addiction and Opioid Crisis and the hearing by the House Committee on Energy and Commerce on the opioid crisis.
During her previous tenure of over 15 years at Pfizer, Inc., she held various leadership roles in global medical affairs and led Pfizer's Global Access program to improve healthcare access for low-income populations in the developing world through approaches that were commercially viable and sustainable.
Acadia is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. Acadia has developed and commercialised the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Acadia also has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, schizophrenia, major depressive disorder, and Rett syndrome.
Login
Username:

Password:


Related Headlines